Clifford E. Kashtan (2020) An update on current and potential genetic insights and diagnosis of Alport syndrome, Expert Opinion on Orphan Drugs, 8:6, 179-188, DOI: 10.1080/21678707.2020.1784722

Gross, O., Tönshoff, B., Weber, L. T., Pape, L., Latta, K., Fehrenbach, H., Lange-Sperandio, B., Zappel, H., Hoyer, P., Staude, H., König, S., John, U., Gellermann, J., Hoppe, B., Galiano, M., Hoecker, B., Ehren, R., Lerch, C., Kashtan, C. E., Harden, M., … German Pediatric Nephrology (GPN) Study Group and EARLY PRO-TECT Alport Investigators (2020). A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome. Kidney international97(6), 1275–1286.

Weinstock, B. A., Feldman, D. L., Fornoni, A., Gross, O., Kashtan, C. E., Lagas, S., Lennon, R., Miner, J. H., Rheault, M. N., Simon, J. F., & Workshop Participants (2020). Clinical trial recommendations for potential Alport syndrome therapiesKidney international97(6), 1109–1116.

Kashtan CE. Alport Syndrome: Achieving Early Diagnosis and TreatmentAm J Kidney Dis. 2020;S0272-6386(20)30734-4. doi:10.1053/j.ajkd.2020.03.026

Rheault MN, et al. The Importance of Clinician, Patient and Researcher Collaborations in Alport Syndrome. Pediatr Nephrol. 2020 May;35(5):733-742.

Rheault MN, Smoyer WE. Long-term ACE Inhibition in Alport Syndrome: Are the Benefits Worth the Risks? Kidney Int. 2020 Jun;97(6):1104-1106.

Kashtan CE. Renal Transplantation in Patients With Alport Syndrome: Patient Selection, Outcomes, and Donor Evaluation. Int J Nephrol Renovasc Dis. 2018 Oct 16;11:267-270.

Gross O, Kashtan CE, Rheault MN, et al. A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial With Open-Arm Comparison Indicates Safety and Efficacy of Nephroprotective Therapy With Ramipril in Children With Alport's Syndrome. Kidney Int​​​​​​. 2020 Jun;97(6):1275-1286. 

Weinstock BA, Kashtan CE, Rheault MN, et al. Clinical Trial Recommendations for Potential Alport Syndrome Therapies. Kidney Int. 2020 Jun;97(6):1109-1116.

Kashtan CE. Alport syndrome: facts and opinions. F1000Res. 2017;6:50.

Gross O, Kashtan CE, Rheault MN, et al. Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrol Dial Transplant. 2016;32(6):916-924.

Kashtan CE. Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation. Int J Nephrol Renovasc Dis. 2018;11:267-270.

Kashtan CE, Ding, J., Garosi, G., Heidet, L., Massella, L., Nakanishi, K., . . . Gross, O. (2018). Alport syndrome: A unified classification of genetic disorders of collagen IV α345: A position paper of the Alport Syndrome Classification Working Group. Kidney International,93(5), 1045-1051.

Phelan, P. J., Rheault MN. (2017). Hearing loss and renal syndromes. Pediatric Nephrology,33(10), 1671-1683. doi:10.1007/s00467-017-3835-9

Savige J, Colville D, Rheault MN, et al. Alport Syndrome in Women and Girls. Clin J Am Soc Nephrol. 2016;11(9):1713-20.